Principia Biopharma, a US-based biopharmaceutical company focused on autoimmune diseases and cancer, has received $12.5m in its second trache of a series A round from a consortium including drugs company GlaxoSmithKline’s (GSK) corporate venturing unit.
Alongside GSK’s SR One, which has partner Simeon George on Principia’s board, in the round were venture capital firms New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures and Mission Bay Capital.
In February 2011, Principia completed a tiered A round totaling $36.3m and received the first tranche of…
